康德萊醫械(01501.HK)擬向樑棟科配發200萬股獎勵股份
格隆匯8月19日丨康德萊醫械(01501.HK)宣佈,公司已於2021年5月13日就公司根據股份激勵計劃配發及發行200萬股新內資股接獲中國證監會的批准。中國證監會批准將自2021年5月13日起12個月內有效。
因此,根據日期為2021年5月13日的中國證監會批准以及股東於2021年5月17日舉行之股東周年大會上批准的修訂股份激勵計劃及受限制股份單位授權,董事會已議決於2021年8月19日授予受限制股份單位(相當於同日的200萬股獎勵股份)。公司將在中國證監會批准的有效期內適時向中國證券登記結算有限責任公司申請批准向樑棟科博士配發100萬股新內資股及向股份激勵平台配發100萬股新內資股。
於建議配發完成後,已發行股份總數將為1.68億股。公司擬於適當時候向中國證監會申請根據股份激勵計劃配發餘下300萬股獎勵股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.